Review



class b cpg  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    InvivoGen class b cpg
    Class B Cpg, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1399 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/ODN+1826/pm42274627-70-0-13
    Average 98 stars, based on 1399 article reviews
    class b cpg - by Bioz Stars, 2026-09
    98/100 stars

    Images

    Related Articles

    Adjuvant:

    Article Title: Preliminary evaluation of a DDA cationic liposome-based pulmonary mucosal immunization platform carrying a SARS-CoV-2 spike-derived branched peptide
    Article Snippet: .. The adjuvant used in this study was CpG ODN 1018, a class B CpG ODN (InvivoGen, San Diego, CA, USA; cat. vac-1018-1), with the sequence 5′-TGACTGTGAACGTTCGAGATGA-3′. ..

    Sequencing:

    Article Title: Preliminary evaluation of a DDA cationic liposome-based pulmonary mucosal immunization platform carrying a SARS-CoV-2 spike-derived branched peptide
    Article Snippet: .. The adjuvant used in this study was CpG ODN 1018, a class B CpG ODN (InvivoGen, San Diego, CA, USA; cat. vac-1018-1), with the sequence 5′-TGACTGTGAACGTTCGAGATGA-3′. ..

    Synthesized:

    Article Title: CpG oligodeoxynucleotide-coated chitosan nanoparticles enhance macrophage proinflammatory phenotype in vitro.
    Article Snippet: This study aimed to investigate the effects of CpG oligodeoxynucleotide (CpG-ODNs)-coated chitosan nanoparticles (CNP) on the phenotype of murine macrophages and their proinflammatory cytokine profile in vitro.. CNP-CpG-ODNs loaded with FITC-scrambled siRNA were prepared using the ionotropic gelation method.. Peritoneal macrophages were isolated and exposed to CNP-CpG-ODNs.

    Control:

    Article Title: CpG oligodeoxynucleotide-coated chitosan nanoparticles enhance macrophage proinflammatory phenotype in vitro.
    Article Snippet: This study aimed to investigate the effects of CpG oligodeoxynucleotide (CpG-ODNs)-coated chitosan nanoparticles (CNP) on the phenotype of murine macrophages and their proinflammatory cytokine profile in vitro.. CNP-CpG-ODNs loaded with FITC-scrambled siRNA were prepared using the ionotropic gelation method.. Peritoneal macrophages were isolated and exposed to CNP-CpG-ODNs.



    Similar Products

    class b cpg  (InvivoGen)
    98
    InvivoGen class b cpg
    Class B Cpg, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/ODN+1826/pm42274627-70-0-13
    Average 98 stars, based on 1 article reviews
    class b cpg - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    alhydrogel adjuvant 2%  (InvivoGen)
    98
    InvivoGen alhydrogel adjuvant 2%
    Alhydrogel Adjuvant 2%, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/Alhydrogel+adjuvant+2%25/custom%40vac-alu-50%4042263787
    Average 98 stars, based on 1 article reviews
    alhydrogel adjuvant 2% - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    class b cpg odn  (InvivoGen)
    94
    InvivoGen class b cpg odn
    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
    Class B Cpg Odn, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/ODN+1018+VacciGrade/pmc13260544-43-11-15
    Average 94 stars, based on 1 article reviews
    class b cpg odn - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    class b cpg oligodeoxynucleotide odn 2006  (InvivoGen)
    97
    InvivoGen class b cpg oligodeoxynucleotide odn 2006
    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
    Class B Cpg Oligodeoxynucleotide Odn 2006, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/ODN+2006/pm42026241-39-12-23
    Average 97 stars, based on 1 article reviews
    class b cpg oligodeoxynucleotide odn 2006 - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    class b cpg oligonucleotide  (InvivoGen)
    97
    InvivoGen class b cpg oligonucleotide
    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
    Class B Cpg Oligonucleotide, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/ODN+2006/pmc13033549-81-59-75
    Average 97 stars, based on 1 article reviews
    class b cpg oligonucleotide - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    class b cpg odn 1826  (InvivoGen)
    98
    InvivoGen class b cpg odn 1826
    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
    Class B Cpg Odn 1826, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/ODN+1826/bio_rxiv__64898__2026__01__16__699962-257-6-11
    Average 98 stars, based on 1 article reviews
    class b cpg odn 1826 - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    human tlr9 ligand class b cpg oligonucleotides  (InvivoGen)
    97
    InvivoGen human tlr9 ligand class b cpg oligonucleotides
    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
    Human Tlr9 Ligand Class B Cpg Oligonucleotides, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/ODN+2006/bio_rxiv__64898__2025__12__23__695947-56-9-18
    Average 97 stars, based on 1 article reviews
    human tlr9 ligand class b cpg oligonucleotides - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    synthetic class b 2007 cpg oligodeoxynucleotide odn  (InvivoGen)
    94
    InvivoGen synthetic class b 2007 cpg oligodeoxynucleotide odn
    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
    Synthetic Class B 2007 Cpg Oligodeoxynucleotide Odn, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/ODN+2007/pm41418602-58-1-15
    Average 94 stars, based on 1 article reviews
    synthetic class b 2007 cpg oligodeoxynucleotide odn - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    cpg class b  (InvivoGen)
    98
    InvivoGen cpg class b
    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
    Cpg Class B, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/class+b+cpg+odn/ODN+1826/pm40743682-108-5-12
    Average 98 stars, based on 1 article reviews
    cpg class b - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG ODN, and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.

    Journal: Frontiers in Immunology

    Article Title: Preliminary evaluation of a DDA cationic liposome-based pulmonary mucosal immunization platform carrying a SARS-CoV-2 spike-derived branched peptide

    doi: 10.3389/fimmu.2026.1824741

    Figure Lengend Snippet: Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG ODN, and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.

    Article Snippet: The adjuvant used in this study was CpG ODN 1018, a class B CpG ODN (InvivoGen, San Diego, CA, USA; cat. vac-1018-1), with the sequence 5′-TGACTGTGAACGTTCGAGATGA-3′.

    Techniques: Expressing, CCK-8 Assay, Control